These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 18005335)

  • 1. Selectivity-determining residues in Plk1.
    Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
    Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the catalytic domain of human polo-like kinase 1.
    Kothe M; Kohls D; Low S; Coli R; Cheng AC; Jacques SL; Johnson TL; Lewis C; Loh C; Nonomiya J; Sheils AL; Verdries KA; Wynn TA; Kuhn C; Ding YH
    Biochemistry; 2007 May; 46(20):5960-71. PubMed ID: 17461553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
    Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
    Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Johnson EF; Stewart KD; Woods KW; Giranda VL; Luo Y
    Biochemistry; 2007 Aug; 46(33):9551-63. PubMed ID: 17655330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).
    Wäsch R; Hasskarl J; Schnerch D; Lübbert M
    Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
    Grinshtein N; Datti A; Fujitani M; Uehling D; Prakesch M; Isaac M; Irwin MS; Wrana JL; Al-Awar R; Kaplan DR
    Cancer Res; 2011 Feb; 71(4):1385-95. PubMed ID: 21303981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
    Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
    J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
    Elling RA; Fucini RV; Romanowski MJ
    Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):909-18. PubMed ID: 18703838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pinning down the polo-box domain.
    Lee KS; Idle JR
    Chem Biol; 2008 May; 15(5):415-6. PubMed ID: 18482691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.
    Emmitte KA; Adjabeng GM; Andrews CW; Alberti JG; Bambal R; Chamberlain SD; Davis-Ward RG; Dickson HD; Hassler DF; Hornberger KR; Jackson JR; Kuntz KW; Lansing TJ; Mook RA; Nailor KE; Pobanz MA; Smith SC; Sung CM; Cheung M
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1694-7. PubMed ID: 19237286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
    Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
    Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
    Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
    Beria I; Ballinari D; Bertrand JA; Borghi D; Bossi RT; Brasca MG; Cappella P; Caruso M; Ceccarelli W; Ciavolella A; Cristiani C; Croci V; De Ponti A; Fachin G; Ferguson RD; Lansen J; Moll JK; Pesenti E; Posteri H; Perego R; Rocchetti M; Storici P; Volpi D; Valsasina B
    J Med Chem; 2010 May; 53(9):3532-51. PubMed ID: 20397705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLK1 inhibitors: setting the mitotic death trap.
    Plyte S; Musacchio A
    Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
    Reindl W; Strebhardt K; Berg T
    Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
    Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
    Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
    Egert-Schmidt AM; Dreher J; Dunkel U; Kohfeld S; Preu L; Weber H; Ehlert JE; Mutschler B; Totzke F; Schächtele C; Kubbutat MH; Baumann K; Kunick C
    J Med Chem; 2010 Mar; 53(6):2433-42. PubMed ID: 20170163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
    Fucini RV; Hanan EJ; Romanowski MJ; Elling RA; Lew W; Barr KJ; Zhu J; Yoburn JC; Liu Y; Fahr BT; Fan J; Lu Y; Pham P; Choong IC; VanderPorten EC; Bui M; Purkey HE; Evanchik MJ; Yang W
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5648-52. PubMed ID: 18793847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.